459 related articles for article (PubMed ID: 21941546)
1. Pathobiology and chemoprevention of bladder cancer.
Tanaka T; Miyazawa K; Tsukamoto T; Kuno T; Suzuki K
J Oncol; 2011; 2011():528353. PubMed ID: 21941546
[TBL] [Abstract][Full Text] [Related]
2. Genetic and molecular markers of urothelial premalignancy and malignancy.
Cordon-Cardo C; Cote RJ; Sauter G
Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
[TBL] [Abstract][Full Text] [Related]
3. Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.
Cordon-Cardo C; Sheinfeld J
World J Urol; 1997; 15(2):112-9. PubMed ID: 9144901
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic alterations as intermediate end points in chemoprevention studies.
Conti CJ; Gimenez-Conti IB
IARC Sci Publ; 1996; (139):249-60. PubMed ID: 8923035
[TBL] [Abstract][Full Text] [Related]
5. Molecular events in bronchogenic carcinoma and their implications for therapy.
Toloza EM; Roth JA; Swisher SG
Semin Surg Oncol; 2000 Mar; 18(2):91-9. PubMed ID: 10657910
[TBL] [Abstract][Full Text] [Related]
6. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
7. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.
Leone A; Diorio G; Sexton W; Schell M; Alexandrow M; Fahey JW; Kumar NB
Oncotarget; 2017 May; 8(21):35412-35424. PubMed ID: 28423681
[TBL] [Abstract][Full Text] [Related]
10. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of bladder cancer.
Kamat AM; Lamm DL
Urol Clin North Am; 2002 Feb; 29(1):157-68. PubMed ID: 12109342
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
[TBL] [Abstract][Full Text] [Related]
13. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research.
Hursting SD; Nunez NP; Patel AC; Perkins SN; Lubet RA; Barrett JC
Mutat Res; 2005 Aug; 576(1-2):80-92. PubMed ID: 15990122
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention: phytoprevention and chemoprevention of colorectal cancer.
Turini ME; DuBois RN
Hematol Oncol Clin North Am; 2002 Aug; 16(4):811-40. PubMed ID: 12418050
[TBL] [Abstract][Full Text] [Related]
15. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
16. Mutation of cell cycle regulators and their impact on superficial bladder cancer.
Rabbani F; Cordon-Cardo C
Urol Clin North Am; 2000 Feb; 27(1):83-102, ix. PubMed ID: 10696248
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in mouse lung tumors: implications for cancer chemoprevention.
Herzog CR; Lubet RA; You M
J Cell Biochem Suppl; 1997; 28-29():49-63. PubMed ID: 9589349
[TBL] [Abstract][Full Text] [Related]
18. Development of chemopreventive agents for bladder cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16I():1-12. PubMed ID: 1305671
[TBL] [Abstract][Full Text] [Related]
19. Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.
John BA; Said N
Oncotarget; 2017 Aug; 8(34):57766-57781. PubMed ID: 28915710
[TBL] [Abstract][Full Text] [Related]
20. A molecular genetic model of human bladder cancer pathogenesis.
Reznikoff CA; Belair CD; Yeager TR; Savelieva E; Blelloch RH; Puthenveettil JA; Cuthill S
Semin Oncol; 1996 Oct; 23(5):571-84. PubMed ID: 8893868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
